AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02509689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Global Z-Score Neurofeedback Training
Description: The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.~Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions.
Study NCT03736421 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral Intravenous Analysis (PIVA)
Description: Non-invasive measurement of peripheral intravenous waveform analysis (PIVA) obtained by connecting an Edwards standard transducer to a universal adaptor or stopcock on a peripheral IV
Study NCT03736421 — intervention group
Intervention type: PROCEDURE
Intervention: Non-invasive fluid response measure
Description: To measure the stroke volume and changes in stroke volume in response to a passive leg raise (PLR) maneuver and fluid administration.
Study NCT03736421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Passive leg raise (PLR)
Description: Test to predict cardiac output and fluid responsiveness
Study NCT02387021 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous femoral nerve block
Study NCT02387021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block
Study NCT02387021 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous adductor canal block
Study NCT02387021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block
Study NCT02387021 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infragluteal Sciatic nerve block
Study NCT02387021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: infragluteal Sciatic nerve block
Study NCT02387021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2%
Study NCT02535598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced presentation
Description: The material of the intervention is designed to be as appealing as possible with clear organization, animated presentations, ample illustrations, etc.
Study NCT02535598 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal support
Description: Participants receive semi-standardized support once a week and there will be no formal training or competence.
Study NCT02535598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced support
Description: Participants are offered daily support through the internet from trained therapists.
Study NCT02387021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Study NCT02387021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Study NCT02387021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Study NCT01670032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: CD07223 1.5 % Topical Gel BID
Description: Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
Study NCT01670032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: CD07223 1.5% Topical Gel TID
Description: Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
Study NCT01670032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: CD07223 vehicle gel BID
Description: Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
Study NCT01670032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: CD07223 vehicle gel TID
Description: Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
Study NCT01894620 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS real-sham
Description: In this intervention patients receive 4 weeks of rTMS treatment with real coil and then 4 weeks of treatment with sham coil; there will be 4 weeks of break between the two blocks of treatment.
Study NCT01894620 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS real-sham
Description: In this intervention patients receive 4 weeks of rTMS treatment with real coil and then 4 weeks of treatment with sham coil; there will be 4 weeks of break between the two blocks of treatment.
Study NCT01894620 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS sham-real
Description: In this intervention patients receive 4 weeks of rTMS treatment with sham coil and then 4 weeks of treatment with real coil; there will be 4 weeks of break between the two blocks of treatment.
Study NCT01894620 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS sham-real
Description: In this intervention patients receive 4 weeks of rTMS treatment with sham coil and then 4 weeks of treatment with real coil; there will be 4 weeks of break between the two blocks of treatment.
Study NCT02877680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T1Doing Well
Description: Strengths-based mobile health (mHealth) app for parents of adolescents with type 1 diabetes, which will prompt parents to recognize and reinforce their adolescents' diabetes-related strength behaviors
Study NCT02457078 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postnatal Dietary Supplement
Description: Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
Study NCT02457078 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Supplement
Description: Placebo Supplement:soybean oil and α-tocopherol (vitamin E)
Study NCT02720783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary
Description: Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary
Study NCT01690117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GE-REACH-program
Description: The intervention program Resources to Enhance Alzheimer's Caregivers Health -second step (REACH II) is a multimodal, individualized and structured multi-component intervention program for family caregivers
Study NCT03103438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-089
Study NCT02720783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus Econazole nitrate 150 mg vaginal pessary
Study NCT02720783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus Benzydamine HCl 6 mg vaginal pessary
Study NCT02720783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal pessary
Study NCT01795183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMISULPRIDE
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT02739841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilator hyperinflation
Description: 4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial.
Study NCT02739841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physical therapy
Description: The patient will be received vibration and passive of the both upper extremity.
Study NCT01075321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given orally
Study NCT01075321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study NCT01551121 — intervention group
Intervention type: OTHER
Intervention: It will then allow them to intervene at the right time and the right place
Description: The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy.
Study NCT00887471 — intervention group
Intervention type: PROCEDURE
Intervention: PITA or T&A
Description: PITA - Microdebrider-assisted Partial Intracapsular Tonsillectomy and Adenoidectomy T\&A - Bove Electrocautery Complete Tonsillectomy and Adenoidectomy
Study NCT03660254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tai chi
Description: tai chi exercise intervention，two times a week and each time cost one hour
Study NCT02475733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime -avibactam
Description: Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
Study NCT02475733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Randomisation (3:1) to CAZ AVI plus metronidazole or meropenem treatment
Study NCT02475733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
Study NCT04264416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WB-EMS
Description: 16 weeks of WB-EMS
Study NCT01075321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03684278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of 5 mg/kg Infliximab
Description: Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
Study NCT03684278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of 10 mg/kg Infliximab
Description: Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
Study NCT03684278 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride (Placebo)
Description: 250 ml (500 ml if patient weighs over 100 kg) of 0.9% Sodium Chloride
Study NCT01075321 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies
Study NCT01075321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Optional correlative studies
Study NCT05871489 — intervention group
Intervention type: DRUG
Intervention: Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)
Description: Bdq, Lzd, Lfx, Dlm, Cfz for nine months, with extension to 12 months as needed
Study NCT05871489 — intervention group
Intervention type: DRUG
Intervention: Bdq, Lzd, Lfx, Cfz, Cs (9-12 months)
Description: Bdq, Lzd, Lfx, Cfz, Cs for nine months, with extension to 12 months as needed
Study NCT05871489 — intervention group
Intervention type: DRUG
Intervention: Bdq, Lzd, Lfx, Z, Dlm (9-12 months)
Description: Bdq, Lzd, Lfx, Z, Dlm for nine months, with extension to 12 months as needed
Study NCT01075321 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Optional correlative studies
Study NCT01075321 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Optional correlative studies
Study NCT02030678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Irinotecan monotherapy (trade name: Aili; batches 180103AG \[40 mg\] and 171231AG \[100 mg\]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
Study NCT04498884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rinsulin® mix 30/70
Description: one subcutaneous injection at a dose of 0.4 IU/kg
Study NCT04498884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rinsulin® mix 30/70
Description: one subcutaneous injection at a dose of 0.4 IU/kg
Study NCT04498884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin® M3
Description: one subcutaneous injection at a dose of 0.4 IU/kg
Study NCT04498884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin® M3
Description: one subcutaneous injection at a dose of 0.4 IU/kg
Study NCT02305797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release lorazepam
Description: Extended-release lorazepam capsules
Study NCT02305797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT03562702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard IV Rehydration Therapy
Description: IV rehydration group receiving a Normal Saline bolus of IVF (usually 20 ml/kg)
Study NCT03562702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV Rehydration Therapy
Description: IV rehydration group receiving a Normal Saline bolus of IVF (usually 20 ml/kg)
Study NCT03562702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Therapy (ORT)
Description: Speedlyte oral solution as rehydration therapy based on participant's weight (10 m/l kg over one hour). Total of 150 ml/kg over 24 hours prior to discharge
Study NCT03562702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Rehydration Therapy (ORT)
Description: Speedlyte oral solution as rehydration therapy based on participant's weight (10 m/l kg over one hour). Total of 150 ml/kg over 24 hours prior to discharge
Study NCT03508830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: 5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.
Study NCT03508830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: 5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.
Study NCT03547648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peak airway pressure
Description: Patients' peak airway pressures will be raised to observe intraoperative bleeding in thyroidectomy surgery. Aim is to prevent postoperative bleeding.
Study NCT06645990 — intervention group
Intervention type: DEVICE
Intervention: Impella
Description: LV unloading with Impella (ECMELLA) before or within 24 h of ECMO initiation
Study NCT06645990 — intervention group
Intervention type: DEVICE
Intervention: IABP
Description: LV unloading with IABP before or within 24 h of ECMO initiation
Study NCT02475499 — intervention group
Intervention type: DRUG
Intervention: DPP-4 inhibitors
Description: Ever-use of DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
Study NCT02475499 — intervention group
Intervention type: DRUG
Intervention: GLP-1 analogs
Description: Ever-use of GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
Study NCT02475499 — intervention group
Intervention type: DRUG
Intervention: Sulfonylureas
Description: Ever-use of sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
Study NCT02475499 — intervention group
Intervention type: DRUG
Intervention: Biguanides
Description: Ever-use of biguanides (ATC A10BA) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
Study NCT02475499 — intervention group
Intervention type: DRUG
Intervention: Thiazolidinediones
Description: Ever-use of thiazolidinediones (ATC A10BG) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
Study NCT02475499 — intervention group
Intervention type: DRUG
Intervention: Alpha-glucosidase inhibitors
Description: Ever-use of alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
Study NCT02475499 — intervention group
Intervention type: DRUG
Intervention: Meglitinides
Description: Ever-use of meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
Study NCT03252899 — intervention group
Intervention type: OTHER
Intervention: Survey therapists
Description: A survey was conducted among therapists on upper limb treatment after stroke.
Study NCT03252899 — intervention group
Intervention type: OTHER
Intervention: Survey patients
Description: A survey was conducted among stroke survivors on upper limb treatment after stroke.
Study NCT04494919 — intervention group
Intervention type: DEVICE
Intervention: Ultrafine Endoscope
Description: The reversal of the normal colonoscope (CV-260SL; Olympus, Tokyo, Japan) along the guidewire to replace the UFE (GIF-XP260NS; Olympus, Tokyo, Japan).
Study NCT04376996 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NO intervention planned due to the observational study design - only a diagnostic testing
Description: Only a diagnostic tests are planned: SARS-CoV-2 RNA in nasopharyngeal samples and anti-SARS-CoV-2 antibodies in blood
Study NCT01807130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated HF/EP Referral
Description: Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology (EP) with recommendations to consider those therapies that are not in compliance with guidelines.
Study NCT01807130 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Registry Arm)
Description: Patients assigned to the registry will receive referral to specialists in HF or EP as deemed necessary by the patients physicians.
Study NCT00503841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
Study NCT00503841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Assessed at the time of the initial biopsy and at the time of surgery.
Study NCT00503841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00503841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: 14 days prior to surgery
Study NCT00503841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: 14 days after taking study drug erlotinib hydrochloride.
Study NCT00503841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: 14 days after taking study drug erlotinib hydrochloride.
Study NCT03486041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Behavior Modification
Description: Behavior therapy approach to BFRBs involving targeted intervention tactics chosen in accordance with the modality of functioning (ex: Sensory, Cognitive.....) seeming to cause the most frequent and problematic urges to engage in the BFRB. Therapist and client work together, using careful assessments including detailed self-monitoring, to determine what behavioral methods will suffice for lasting change.
Study NCT03486041 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention
Description: Weekly brief calls from therapist to check on safety and clinical status. No focus on TTM.
Study NCT04358926 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen therapy
Description: 8 sessions in 4 days of breathing 100% oxygen in 2.2 ATA. Each session is 60 minutes. 1 meter/minute compression/decompression
Study NCT03454594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level laser hemotherapy
Description: semiconductor laser therapeutic instrument irradiate the circulating blood in the vessels of left hand acupoint and the mucosal tissue in the nasal cavity